Wolde Hailu Demissie: Moving Beyond the 4.5-Hour Window in Wake-Up Stroke
Wolde Hailu Demissie, Internist at RDDMH, shared on LinkedIn about a recent article by Mehari Gebreyohanns et al, published in Frontiers, adding:
”Wake-up stroke is a stroke with unknown onset time.
Often excluded from tPA treatment due to the absence of a standardized approach.
Interestingly 25% of acute ischemic strokes are wake-up strokes.
Due to the uncertain onset of symptoms, only about 8–27% of patients experiencing wake-up strokes receive thrombolytic therapy as 4.5hr not include those patient .
The bottom line is: MRI can be crucial in estimating the ischemic core and penumbra, guiding decisions on thrombolytic therapy for these patients .
30% of patients with wake-up stroke with negative fluid attenuated inversion recovery (FLAIR) and a visible acute ischemic lesion on diffusion weighted imaging (DWI) findings on MRI, or simply MRI mismatch, may be candidates for thrombolytic therapy.
Both tPA and EVT in these patients improve functional outcomes without increasing the risk of death.
In general MRI revolutionized stroke management with early papers on New England Journal of Medicine to support the the same concept.
Negative FLAIR with visible DWI is what you look for the stroke management not only 4.5 hr!
And above MRI finding may perisist up to 9hr so imaging with this hr for wake up stroke from last time he/she went to bed is paramount important to 4.5 hours.”
Title: Identifying wakeup stroke routine treatments in the emergency departments
Authors: Mehari Gebreyohanns, Sidarrth Prasad, Kim D. Barker, Joshua D. E. Amos, Erica M. Jones, Lindsay M. Riskey, Daiwai M. Olson, Asmiet K. Techan, Ty A. Johnson, Nneka L. Ifejika
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?